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ABSTRACT 
Nanotechnology is and will be the future of several fields and medicine is one of them. The use of nanoparticles in the treatment of psychotic and 
cancer problems is analyzed in this report. Psychotic treatment has been effective due to specific nanoparticles like haloperidol and RISP, and 
these combinations are linked with other nanoparticles to treat other diseases. Nanoparticles have extended applications with a high degree of 
effectiveness to treat cancer cells due to the quick delivery, and targeted process and the same is detailed in the review sheet. Oligonucleotides 
combined with nanoparticles have greater efficiencies.  
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Introduction 
Modern medicine uses nanoparticles for various drug 
delivery and treatment systems such as magnetic resonance 
imaging, cancer treatment, tumor treatment, and cell 
treatment1-9. Nanotechnology has allowed the researchers to 
experiment with different combinations of nanoparticles to 
apply the best to the biological devices and develop proper 
engineered materials to the patients. This review begins with 
an introduction on the need for nanoparticles followed by 
two different sections to explain the impact of nanoparticles 
in the treatment of tumor and lung cancer10-16.  
The need for nanoparticles 
Nanotechnology has gained widespread usage in the field of 
medicine. Nanoparticles have been used as a drug delivery 
material to deliver light, heat and other substances to the 
affected cells17-23. It is observed that nanoparticles are 
efficient than other drug delivery methods for serious health 
problems such as cancer since nanoparticles can directly 
penetrate to cancer-causing cells and control its activity to a 
greater extent24-27. The targeted delivery is the reason for the 
widespread use of nanoparticles. Further, they dissolve 
within the cell leaving no side effect but a long-term impact 
on the body.  
There are varied combinations of nanomaterials out of which 
solid-lipid and the polymeric nanoparticles tend to achieve 
higher success rate due to the biocompatibility and the 
safety associated with it. The treatment methodology used 
for the tumor can be repeated for lung cancer, too.  
Impact of nanoparticles on brain problems 
There are two types of issues addressed in this section - 
psychological and brain tumor. The modern society has 
shown a high prevalence of psychosis28-32. To control the 
mental problems, antipsychotic medications have now been 
recommended involving nanoparticles that will develop 
building blocks and ensure a slow release process. 
Haloperidol (HP) loaded nanoparticle is used to treat 
schizophrenia and blocks the D2 dopamine receptors. 
Further, the dendrimers are altered to be induced as 
nanoparticles. A popular antipsychotic drug is risperidone 
(RISP) which is required to treat schizophrenia. The process 
of antipsychotic delivery is not researched in depth. 
However, nanoparticle-based administration to the 
treatment of psychotic problems tends to enhance the life of 
the affected individual and prove biocompatibility33-38. 
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For the brain tumor, it is a severe case though nanoparticles 
are available in abundance in the market. The problem is the 
absence of a substance that can control brain tumor-like 
glioblastoma at an earlier stage. Nanoparticle plays a role in 
such situations. Further, the brain tumor is treated with 
chemotherapy that has high cytotoxicity and nanoparticles 
tend to eliminate the blood-brain barriers29. In vivo and in 
vitro are the nanomaterials where nanoparticles have the 
abilities to link and bond with macromolecules and ease the 
circulation29.  
Gold nanoparticles have been very useful to perform brain 
targeting followed by drug delivery. The electrons are 
conducted on the metal surface, and there is an excitation by 
light. Serine-arginine-leucine (SRL) modified dendrimers are 
found to have higher rates of transfusion, and the toxicity 
level is hugely less. The problem faced in the treatment of 
brain tumor is the specificity and targeting39,40. Glioblastoma 
multiforme, a form of brain tumor, is aggressive and makes it 
difficult for the procedure to turn effective. Fibrin binding 
peptide can be induced to treat this case29.  
Polymeric, lipid and magnetic and microbubble 
nanoparticles have been useful in the treatment of brain 
tumor. They have addressed the neoplasm groups and 
reduced the toxicity with the application of nanoparticles. 
These generate proteins needed to control the impact of 
tumor and enhance the success rate of treatment.  
Impact of nanoparticles on lung cancer 
Human cancer is developed due to the excessive expression 
of Bcl-2 which is an anti-apoptotic gene. This expression has 
been controlled with the help of antisense oligonucleotides 
(ASOs) therapy21,22. However, there have been problems in 
the binding affinity and immunity of oligonucleotide. This 
has led to the demand of lipid nanoparticles which can 
increase the overall nuclease stability and the circulation 
time of such oligonucleotides8,21,22. 
  
 
It is true that gapmer design can downregulate the presence 
of cancer and improve the binding affinity. So far, the 
treatment of lung cancer has shown positive results with 
LNP formulation as the in vitro and in vivo activities are high, 
and there is considerable stability which can improve the 
usefulness of the therapy21,22. While antisense 
oligonucleotide combined with lipid nanoparticles is called 
an effective therapy, quaternary amine-tertiary amine 
cationic lipid combination ensures an efficient and cost-
effective treatment, too.  
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The latter works in both in vitro and in vivo gene regulation. 
The nanoparticles slowly invade the affected region and alter 
the surface and charge it to enhance the quality delivery of 
the oligonucleotides. miR-21 plays an essential role in 
regulating the propagation of tumor and cancer. QTsome 
nanoparticles are ideal for inducing strong dosage of the 
therapy without affecting the sensitivity and increasing the 
invasion pace10,11,21-23.  
Conclusion 
The nanoparticle powered treatment for tumor and cancer in 
addition to the psychotic analysis is the most effective and 
sustainable therapy which can change the way other 
diseases are treated. Though varied combinations of 
nanoparticles are chosen, this still serves as a suitable 
therapy mode due to its suitability and biocompatibility, and 
there is no side effect, unlike conventional chemotherapy. As 
a result, it is possible to expect faster results with the 
targeted delivery of therapy.  
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